Vascular Biogenics up as safety panel clears continuation of cancer study

Notable Labs

17/09/2021 13:33

** Israel-based drug developer's shares  VBLT.O  up ~6%
premarket and are set to touch their highest level in two months
of $2.53 at the open
    ** VBLT says independent data safety monitoring committee
(DSMC) has given the clearance to continue ongoing late-stage
study of its experimental cancer treatment, VB-111
    ** DSMC is responsible for setting and monitoring the
implementation of safety standards during clinical studies
    ** In June, co had paused the U.S. recruitment of new
patients as a review by the FDA to compare the manufacturing of
VB-111 at different source sites was pending; enrollment resumed
by the end of August  urn:newsml:reuters.com:*:nGNXM8Ghb
    ** Committee, after its fifth pre-planned review, says late
stage study of VB-111 in ovarian cancer patients can continue
with no changes to trial design  urn:newsml:reuters.com:*:nGNX1PT0jt    
    ** Study, which aims to achieve better survival rates in
patients, plans to enroll 400 patients, 80% of whom have already
been recruited
    ** Up to Thursday's close, stock had risen 26.46% YTD
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))